Despite claims that cannabis or its extracts alleviate all sorts of maladies, the research study has been sparse and the outcomes blended.

Currently 25 states and the District of Columbia have medical marijuana programs. On Nov. 8, Arkansas, Florida and North Dakota will vote on medical marijuana ballot efforts, while Montana will vote on repealing restrictions in its existing law.

What does the readily available research suggest about medical cannabis, and why do we understand so little about it?

From a research study perspective, marijuana is thought about a “filthy” drug due to the fact that it consists of hundreds of compounds with inadequately comprehended effects. That’s why researchers tend to focus on simply one cannabinoid at a time. Only 2 plant-based cannabinoids, THC and cannabidiol, have actually been studied thoroughly, but there might be others with medical benefits that we have no idea about yet.

Exactly what are scientists studying?

Cannabidiol (likewise called CBD), on the other hand, does not interact with cannabinoid receptors. It does not trigger a high. Seventeen states have actually passed laws enabling access to CBD for individuals with certain medical conditions.

Marijuana is promoted as a treatment for many medical conditions. We’ll take a look at two, persistent discomfort and epilepsy, to show exactly what we in fact know about its medical advantages.

Our bodies also produce cannabinoids, called endocannabinoids. Scientists are producing brand-new drugs that modify their function, to better comprehend how cannabinoid receptors work. The objective of these studies is to find treatments that can utilize the body’s own cannabinoids to deal with conditions such as chronic discomfort and epilepsy, rather of utilizing marijuana itself.

While some researchers are examining smoked or vaporized marijuana most are looking at specific marijuana compounds, called cannabinoids.

THC is the main active element of marijuana. It triggers cannabinoid receptors in the brain, triggering the “high” connected with cannabis, as well as in the liver, and other parts of the body. The only FDA-approved cannabinoids that medical professionals can legally recommend are both lab produced drugs much like THC. They are recommended to increase cravings and avoid squandering brought on by cancer or AIDS.

Is it a chronic pain treatment?

Research in individuals recommend that certain conditions, such as persistent pain triggered by nerve injury, may respond to smoked or vaporized marijuana, in addition to an FDA-approved THC drug. But, many of these research studies depend on subjective self-reported pain rankings, a considerable restriction. Just a few controlled medical trials have actually been run, so we can’t yet conclude whether cannabis is an effective discomfort treatment.

An alternative research study method focuses on drug combination treatments, where a speculative cannabinoid drug is combined with an existing drug. A current study in mice combined a low dosage of a THC-like drug with an aspirin-like drug. The mix blocked nerve-related discomfort better than either drug alone.

Research recommends that some people with chronic pain self-medicate with cannabis. However, there is limited human research study on whether marijuana or cannabinoids successfully reduce chronic pain.

In theory, the benefit to combination drug treatments is that less of each drug is needed, and side results are minimized. In addition, some people might react much better to one drug ingredient than the other, so the drug mix might work for more individuals. Comparable research studies have not yet been run in people.

Well-designed epilepsy studies are terribly needed

In people the evidence is much less clear. There are many anecdotes and surveys about the favorable effects of marijuana flowers or extracts for treating epilepsy. But these aren’t the exact same thing as well-controlled scientific trials, which can tell us which types of seizure, if any, react positively to cannabinoids and offer us stronger predictions about how the majority of people react.

Research study in people recommend that certain conditions, such as chronic discomfort caused by nerve injury, may respond to smoked or vaporized marijuana, as well as an FDA-approved THC drug.

We study the marijuana plant, also known as cannabis, and its related chemical compounds. From a research study perspective, cannabis is considered a “dirty” drug since it contains hundreds of compounds with poorly understood results. It triggers cannabinoid receptors in the brain, causing the “high” associated with marijuana, as well as in the liver, and other parts of the body. The objective of these research studies is to find treatments that can use the body’s own cannabinoids to deal with conditions such as chronic discomfort and epilepsy, instead of utilizing marijuana itself.

In spite of some spectacular news stories and widespread speculation on the internet, the use of marijuana to reduce epileptic seizures is supported more by research in rodents than in people.

CBD might engage with anti-epileptic drugs in methods we are still learning about. Care is particularly urged when seeking to medicate children with CBD or marijuana products.

While CBD has acquired interest as a potential treatment for seizures in people, the physiological link in between the two is unknown. Just like persistent discomfort, the few scientific research studies have been done included few clients. Studies of bigger groups of individuals can tell us whether just some patients respond positively to CBD.

Cannabis research is hard

Well-designed studies are the most effective way for us to understand what medical benefits cannabis may have. But research on cannabis or cannabinoids is particularly difficult.

Cannabis and its related compounds, THC and CBD, are on Schedule I of the Controlled Substances Act, which is for drugs with “no currently accepted medical use and a high potential for abuse” and includes Ecstasy and heroin.

In order to study cannabis, a researcher must first request permission at the state and federal level. This is followed by a lengthy federal review process involving inspections to ensure high security and detailed record-keeping.

In our labs, even the very small amounts of cannabinoids we need to conduct research in mice are highly scrutinized. This regulatory burden discourages many researchers.

Designing studies can also be a challenge. Many are based on users’ memories of their symptoms and how much cannabis they use. Bias is a limitation of any study that includes self-reports. Furthermore, laboratory-based studies usually include only moderate to heavy users, who are likely to have formed some tolerance to marijuana’s effects and may not reflect the general population. These studies are also limited by using whole cannabis, which contains many cannabinoids, most of which are poorly understood.

Placebo trials can be a challenge because the euphoria associated with cannabis makes it easy to identify, especially at high THC doses. People know when they are high.

Another type of bias, called expectancy bias, is a particular issue with cannabis research. This is the idea that we tend to experience what we expect, based on our previous knowledge. For example, people report feeling more alert after drinking what they are told is regular coffee, even if it is actually decaffeinated. Similarly, research participants may report pain relief after ingesting cannabis, because they believe that cannabis relieves pain.

The best way to overcome expectancy effects is with a balanced placebo design, in which participants are told that they are taking a placebo or varying cannabis dose, regardless of what they actually receive.

Studies should also include objective, biological measures, such as blood levels of THC or CBD, or physiological and sensory measures routinely used in other areas of biomedical research. At the moment, few do this, prioritizing self-reported measures instead.

Cannabis isn’t without risks

Abuse potential is a concern with any drug that affects the brain, and cannabinoids are no exception. Cannabis is somewhat similar to tobacco, in that some people have great difficulty quitting. And like tobacco, cannabis is a natural product that has been selectively bred to have strong effects on the brain and is not without risk.

Although many cannabis users are able to stop using the drug without problem, 2-6 percentof users have difficulty quitting. Repeated use, despite the desire to decrease or stop using, is known as cannabis use disorder.

As more states more states pass medical cannabis or recreational cannabis laws, the number of people with some degree of cannabis use disorder is also likely to increase.

It is too soon to say for certain that the potential benefits of cannabis outweigh the risks. But with restrictions to cannabis (and cannabidiol) loosening at the state level, research is badly needed to get the facts in order.

Share this: Twitter

Facebook

Tumblr

Reddit

Pinterest

LinkedIn

Pocket

More

Print



Like this: Like Loading...